A predictive study on the preoperative immune inflammatory index and the level of AFU for the early recurrence of hepatocellular carcinoma patients after interventional treatment

doi:10.3877/cma.j.issn.1674-3946.2025.03.005.

Abstract

Abstract:

Objective

To analyze the predictive value of the preoperative immune inflammatory index （SII） and the level of α-L-fucosidase （AFU） for the early recurrence.

Methods

A total of 112 patients who received interventional treatment for hepatocellular carcinoma from July 2021 to July 2023 were selected.According to whether recurrence occurred or not，they were divided into the recurrence group （n=34 cases） and the non-recurrence group （n=78 cases）.The data were imported into SPSS 22.0 for analysis.Measurement data conforming to the normal distribution，such as the levels of SII and AFU，were expressed as （±s），and the independent sample t test was performed.Count data were expressed as［ cases （%）］，and the χ² test was used.Spearman rank correlation analysis was carried out to analyze the correlation between the preoperative levels of SII and AFU and the early recurrence of patients with hepatocellular carcinoma after interventional treatment.The receiver operating characteristic curve （ROC） was used to evaluate the predictive value of the preoperative levels of SII and AFU for the early recurrence of patients with hepatocellular carcinoma after interventional treatment.A P value less than 0.05 was considered to indicate a statistically significant difference.

Results

The preoperative levels of SII and AFU in the recurrence group were higher than those in the non-recurrence group （P＜0.05）.Spearman rank correlation analysis showed that the preoperative levels of SII and AFU were positively correlated with the early recurrence of patients with hepatocellular carcinoma after interventional treatment （r=0.331，0.306，P＜0.05）.The ROC curve showed that the area under the curve （AUC） of the combined prediction of the early recurrence of patients with hepatocellular carcinoma after interventional treatment by the preoperative levels of SII and AFU was 0.947，the sensitivity was 94.12%，and the specificity was 92.31%.The combined predictive efficiency was better than that of each index alone （P＜0.05）.

Conclusion

The preoperative levels of SII and AFU are closely related to the early recurrence of patients with hepatocellular carcinoma after interventional treatment.Measuring the levels of SII and AFU before operation can provide certain predictive value for the early recurrence of patients after operation.

Key words: Liver Neoplasms, Interventional Surgery, Systemic Immune-Inflammation Index, alpha-L-Fucosidase, Early Postoperative Recurrence, Forecasting

Zhankui Wang, Zhiyuan Chen, Wenhui Sun, Qingling Yang, Xiaobin Yang. A predictive study on the preoperative immune inflammatory index and the level of AFU for the early recurrence of hepatocellular carcinoma patients after interventional treatment[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(03): 247-250.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhpwkssxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3946.2025.03.005.

https://zhpwkssxzz.cma-cmc.com.cn/EN/Y2025/V19/I03/247

Figures/Tables 5

组别	例数	性别（例）	年龄（岁， $\overset{ˉ}{x}$ ±s）	体质量指数（kg/m2， $\overset{ˉ}{x}$ ±s）	肿瘤直径（cm， $\overset{ˉ}{x}$ ±s）
组别	例数	男/女	年龄（岁， $\overset{ˉ}{x}$ ±s）	体质量指数（kg/m2， $\overset{ˉ}{x}$ ±s）	肿瘤直径（cm， $\overset{ˉ}{x}$ ±s）
复发组	34	21/13	54. 3±9. 3	23. 8±1. 8	4. 4±0. 8
未复发组	78	51/27	54. 0±10. 1	23. 7±2. 0	4. 4±0. 8
χ ²/t值		0. 135	0. 133	0. 300	0. 531
P值		0. 713	0. 894	0. 765	0. 597
组别	例数	TNM分期（例）	受教育程度（例）	肿瘤数量（例）
组别	例数	Ⅱ /Ⅲ	高中以上/高中及以下	单发/多发
复发组	34	20/14	14/20	22/12
未复发组	78	48/30	29/49	52/26
χ ²/t值		0. 073	0. 160	0. 041
P值		0. 787	0. 689	0. 840
组别	例数	饮酒史（例）	吸烟史（例）	家族史（例）
组别	例数	是/否	是/否	是/否
复发组	34	22/12	16/18	7/27
未复发组	78	54/24	39/39	12/66
χ ²/t值		0. 222	0. 082	0. 455
P值		0. 637	0. 775	0. 500

组别	例数	性别（例）	年龄（岁， $\overset{ˉ}{x}$ ±s）	体质量指数（kg/m2， $\overset{ˉ}{x}$ ±s）	肿瘤直径（cm， $\overset{ˉ}{x}$ ±s）
组别	例数	男/女	年龄（岁， $\overset{ˉ}{x}$ ±s）	体质量指数（kg/m2， $\overset{ˉ}{x}$ ±s）	肿瘤直径（cm， $\overset{ˉ}{x}$ ±s）
复发组	34	21/13	54. 3±9. 3	23. 8±1. 8	4. 4±0. 8
未复发组	78	51/27	54. 0±10. 1	23. 7±2. 0	4. 4±0. 8
χ ²/t值		0. 135	0. 133	0. 300	0. 531
P值		0. 713	0. 894	0. 765	0. 597
组别	例数	TNM分期（例）	受教育程度（例）	肿瘤数量（例）
组别	例数	Ⅱ /Ⅲ	高中以上/高中及以下	单发/多发
复发组	34	20/14	14/20	22/12
未复发组	78	48/30	29/49	52/26
χ ²/t值		0. 073	0. 160	0. 041
P值		0. 787	0. 689	0. 840
组别	例数	饮酒史（例）	吸烟史（例）	家族史（例）
组别	例数	是/否	是/否	是/否
复发组	34	22/12	16/18	7/27
未复发组	78	54/24	39/39	12/66
χ ²/t值		0. 222	0. 082	0. 455
P值		0. 637	0. 775	0. 500

组别	例数	SII	AFU（U/L）
复发组	34	455. 7±30. 8	63. 8±9. 3
未复发组	78	431. 9±29. 6	57. 2±8. 4
t值		3. 861	3. 729
P值		＜0. 001	＜0. 001

肝癌介入术	指标	r	P值
术后早期复发	SII	0. 331	＜0. 001
	AFU	0. 306	0. 001

检验变量	AUC	SE值	P值	95%CI
SII	0. 708	0. 055	＜0. 001	0. 614-0. 790
AFU	0. 692	0. 054	＜0. 001	0. 598-0. 776
联合预测	0. 947	0. 023	＜0. 001	0. 888-0. 981
检验变量	截断值	灵敏度（%）	特异性（%）	约登指数
SII	445. 5	73. 5	71. 8	0. 453
AFU	53. 6　U/L	88. 2	39. 7	0. 280
联合预测	-	94. 1	92. 3	0. 864

References 16

［1］	杨倩，李翠芳，张婉秋.原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析［J/CD］.中华普外科手术学杂志（电子版），2024，18（01）： 33-36.
［2］	王曼.肝癌介入手术患者CT增强扫描的不良反应和护理效果［J］.保健医学研究与实践，2021，18（S1）： 58-60.
［3］	任莎莎，简文，刘自明.系统免疫炎症指数和骨骼肌质量指数与肝硬化合并肝癌患者术后预后的关系［J］.现代肿瘤医学，2020，28（10）： 1693-1697.
［4］	贾成朋，王代宏，陈华，等.可切除性胰腺癌预后术前预测模型的建立及应用［J/CD］.中华普外科手术学杂志（电子版），2023，17（05）： 566-570.
［5］	Fan N，Li P，Zhou Y，et al.Demystifying Lysosomal α-l-Fucosidase in Liver Cancer-Bearing Mice by Specific Two-Photon Fluorescence Imaging［J］.ACS Sens，2022，7（1）： 71-81.
［6］	Deng Y，Zhao Y，Fan W，et al.Preoperative AFU Is a Useful Serological Prognostic Predictor for Colorectal Liver Oligometastasis Patients Undergoing Hepatic Resection［J］.J Cancer，2019，10（21）： 5049-5056.
［7］	中国抗癌协会肝癌专业委员会（CSLC），中国抗癌协会临床肿瘤学协作专业委员会（CSCO），中华医学会肝病学分会肝癌学组.原发性肝癌规范化诊治的专家共识［J］.肝脏，2009，14（03）： 237-245.
［8］	郭飞宇，熊书名，高森，等.肿瘤组织VEGF、CD34表达联合LSM水平预测肝癌患者术后复发的价值［J］.中国现代医学杂志，2023，33（16）： 13-19.
［9］	马立伟，贾志强，陈午盛，等.CalliSpheres载药微球联合碘化油治疗肝癌的临床研究［J/CD］.中华普外科手术学杂志（电子版），2024，18（04）： 369-372.
［10］	谢俊，梁先春，黄绪兰，等.肝癌患者血清VEGF、bFGF水平与癌组织微血管密度及介入术后早期复发的相关性［J］.新疆医科大学学报，2023，46（08）： 1056-1061，1067.
［11］	Polk N，Budai B，Hitre E，et al.Corrigendum： High Neutrophilto-Lymphocyte Ratio （NLR） and Systemic Immune-Inflammation Index （SII） are Markers of Longer Survival After Metastasectomy of Patients With Liver-Only Metastasis of Rectal Cance［rJ］.Pathol Oncol Res，2022，28： 1610658.
［12］	Deng Y，Zhao Y，Fan W，et al.Preoperative AFU Is a Useful Serological Prognostic Predictor for Colorectal Liver Oligometastasis Patients Undergoing Hepatic Resection［J］.J Cancer，2019，10（21）： 5049-5056.
［13］	刘洪恩，辛大平，彭彬.NLR、PLR和SII在肝癌根治术患者中的表达及与预后的相关性［J］.中国医师杂志，2020，22（09）：1352-1355.
［14］	于翔，成思航，曹磊，等.术前全身免疫炎症指数与DEBTACE治疗肝癌患者预后相关性分析［J］.介入放射学杂志，2021，30（05）： 461-465.
［15］	王桂玲，王治海，张香玲，等.血清Sema4 D、BMP-4、AFU与乙肝相关肝癌患者临床病理特征及预后的关系［J］.中国肿瘤外科杂志，2021，13（02）： 185-190.
［16］	王芳芳，张国范，王琪，等.HBV感染原发性肝癌患者GP73和AFU与25（OH）D3 及其与TACE术后复发转移的关系［J］.中华医院感染学杂志，2023，33（11）： 1660-1664.

[1]	Xinxin Xie, Meiying Han, Chunyan Yang, Qinghua Shen, Fengmin Liu, Cong Li, Dezhi Zhang, Weikai Lei. Early predictive value of combined indicators for moderate to severe bronchopulmonary dysplasia in premature infants [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(06): 611-618.
[2]	Feng Shen, Kui Wang, Jianwei Liu. The current status，challenges，and development of laparoscopic liver cancer surgery in China [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(03): 237-240.
[3]	Jianqian Cai, Xinyu Bi, Bowen Xu. Challenges and strategies in laparoscopic hepatectomy for liver cancer patients in China [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(03): 241-244.
[4]	Haitao Sheng, Mingrui Dou, Junjie Wang, Xiaolong Xiu, Jianmao Yang, Changcheng Dong. Application of individualized hepatic segmentation based on CT three-dimensional visualization technology in anatomical hepatectomy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(03): 258-261.
[5]	Danfeng Shen, Peng Chang, Yingchao Lu, Hongxing Xu, Qiang Gu. Early prediction value of PCT and CRP on severity of acute cholangitis and construction of nomogram model [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(02): 192-195.
[6]	Xiaowei Chang, Yu Cai, Zhiyong Zhao, Wei Zhang. Efficacy and safety analysis of high intensity focused ultrasound ablation combined with hepatic arterial chemoembolization in the treatment of primary hepatocellular carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 56-59.
[7]	Quanyou Lai, Yuan Gao, Jianlin Wang, Shibin Qu, Dan Wei, Wei Peng. Effects of 3D reconstruction technology combined with laparoscopic precision hepatectomy on the levels of CD4+, CD8+ and immunoglobulin in patients with liver cancer after surgery [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 651-654.
[8]	and Pancreatic Disease Prevention and Control Specialty Society of Chinese Prevention Medicine Association Hepatobiliary, Branch of China International Exchange and Promotive Association for Medical and Healthcare Hepato-Oncology. Chinese expert consensus on precision guidance technology in diagnosis and treatment of liver tumors（2024 edition） [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(02): 145-157.
[9]	Chengshu Yu, Hongzhi Liu, Kecan Lin, Qizhu Lin, Tingfeng Huang, Weiping Zhou, Zhangjun Cheng, Jianying Lou, Shuguo Zheng, Xinyu Bi, Jianming Wang, Wei Guo, Fuyu Li, Jian Wang, Yamin Zheng, Jingdong Li, Shi Cheng, Yongyi Zeng. Risk factors of very early recurrence of intrahepatic cholangiocarcinoma after surgery [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 53-59.
[10]	Jiajun Li, Sile Wan, Chaoyang Lu. Clinical analysis of bile leakage after surgical resection of central hepatic tumors [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 87-91.
[11]	Feng Qiu, Tianchi Yang, Wei Han. Safety and efficacy of laparoscopic ultrasound-guided radiofrequency ablation for malignant liver tumors [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 102-106.
[12]	Jiqing Shi, Kun Li, Yifeng Chen. Rare giant bile duct cyst with new-onset liver neoplasm nine years after surgary: a cast report [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 126-127.
[13]	Yifan Li, Diwen Zhu, Weixin Ren, Yingjun Bao, Junpeng Gu, Haixiao Zhang, Gengfei Cao, Weizheng Ji. Role of serum GP73 level in the evaluation of TACE efficacy for primary liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 825-830.
[14]	Jingming Lu, Dawei Han, Yaoxing Ren, Tianxiao Huang, Junxi Xiang, Xufeng Zhang, Yi Lyu, Fumin Wang. Meta-analysis of lymph node metastasis prediction of intrahepatic cholangiocarcinoma based on preoperative radiomics [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 852-858.
[15]	Xueyun Wu, Xiaojun Hu, Yingfang Fan. Evaluation and prediction of residual liver regeneration ability for hepatectomy [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 894-897.

Please choose a citation manager

Content to export